Here’a what happened.
Batches of Irbesartan tablets are being recalled for possibly having too much carcinogen. The FDA has also made a statement on this but have not given an exact reason for the recall. Here’s everything you need to know about the recall.
The recall stated, “certain tested [active pharmaceutical ingredient] batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbeartan.” The high amount of carcinogen would have made a significant impact on a person’s body if they have taken the medication.
The list of recalls start with Irbesartan, 75 mg with lot Nos. H000843, H805727, H901579, H000844, H000964, H804311, H805267, H805268, H805269, H805725, H805726, H901497, H901577, H901578, and H902258. Irbesartan, 150 mg with lot Nos. H804403, H805251, H805640, H901580, H804492, H805252, H805253, H805641, H805642, H805643, H901581, H902139, and H902140.
* Additional Disclaimer: All content provided by this newsletter is for informational and educational purposes only and is not meant to represent trade, investment, or healthcare recommendations.